NCCN 2010 Congress Series: Respiratory Tract Cancers™ - Event Summary | Online Registration by Cvent

NCCN 2010 Congress Series: Respiratory Tract Cancers™

Summary


This Congress is a full-day educational program designed to provide an in-depth analysis of the evidence and clinical decision-making that led to the development of the NCCN Guidelines™ for Head and Neck Cancers, Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and CNS Metastases, collectively Respiratory Tract Cancers. Participants will learn how to implement the recommendations within the NCCN Guidelines into their practice and gain a clear understanding of the most up-to-date treatment recommendations for these cancers.

The impact of these cancers is quite significant. In 2009, it is estimated that there will be approximately 48,010 new cases of oral cavity, pharyngeal, and laryngeal cancers. This accounts for about 3% of new cancer cases in the United States. Most patients with non-small cell lung cancer (NSCLC) have advanced disease (stage IIIB or IV) at diagnosis. Studies show that histology and other criteria can be used to select the most appropriate therapy for patients with advanced NSCLC. In 2009, it is estimated there will be 219,440 new cases of lung cancer, and 159,390 estimated deaths. Small cell lung cancer (SCLC) accounts for 15% of all lung cancers. Intracranial involvement is very common in many types of cancer; almost a third of lung cancer patients develop metastases to the brain. A thorough assessment of the patient situation including the performance status and the location, number, and size of metastatic sites is critical in determining the best treatment scheme for the individual patient.

OPEN HERE PLEASE:
NCCN 2010 Congress Series: Respiratory Tract Cancers™ - Event Summary | Online Registration by Cvent